# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001140361-21-034290
Filing Date
2021-10-12
Accepted
2021-10-12 08:00:31
Documents
8
Period of Report
2021-12-03

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | ny20000819x1_def14a.htm | DEF 14A | 951313
2 |  | logo_galectinx1.jpg | GRAPHIC | 26119
3 |  | ny20000819x1_apa01.jpg | GRAPHIC | 31153
4 |  | ny20000819x1_apa02.jpg | GRAPHIC | 16775
5 |  | ny20000819x1_pc01.jpg | GRAPHIC | 752413
6 |  | ny20000819x1_pc02.jpg | GRAPHIC | 528733
7 |  | sig_jlewis.jpg | GRAPHIC | 12813
8 |  | sig_jwcallicutt.jpg | GRAPHIC | 17818
| Complete submission text file | 0001140361-21-034290.txt |  | 2859716

Mailing Address 4960 PEACHTREE INDUSTRIAL BOULEVARD SUITE 240 NORCROSS GA 30071
Business Address 4960 PEACHTREE INDUSTRIAL BOULEVARD SUITE 240 NORCROSS GA 30071 678-620-3186
GALECTIN THERAPEUTICS INC (Filer) CIK: 0001133416 (see all company filings)

EIN.: 043562325 | State of Incorp.: NV | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-31791 | Film No.: 211316939
SIC: 2834 Pharmaceutical Preparations